open access

Ahead of print
Original Article
Published online: 2018-09-13
Get Citation

Increased systemic arterial stiffness in patients with chronic thromboembolic pulmonary hypertension

Monika Sznajder, Olga Dzikowska-Diduch, Katarzyna Kurnicka, Marek Roik, Dominik Wretowski, Piotr Pruszczyk, Maciej Kostrubiec
DOI: 10.5603/CJ.a2018.0109
·
Pubmed: 30234892

open access

Ahead of print
Original articles
Published online: 2018-09-13

Abstract

Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication   of venous thromboembolism (VTE) resulting from non-dissolving thromboembolic in the pulmonary arteries. Previous observations indicate a higher prevalence of atherosclerosis and cardiovascular risk factors in patients with VTE and CTEPH. The purpose of the present study was to evaluate the arterial stiffening assessed by pulse wave velocity (PWV), a marker of arterial stiffness, in CTEPH patients in comparison with a matched control group (CG). Methods: The study group consisted of 26 CTEPH patients (9 male and 17 female, age 69 ± 10 years) and 22 CG (10 male, 12 female, age 67 ± 8 years). In all subjects a physical examination, carotid-femoral PWV and transthoracic echocardiography (TTE) were performed. Right heart catheterization was done in all CTEPH. Results: CTEPH patients had significantly higher PWV than CG (10.3 ± 2.5 m/s vs. 9 ± 1.3 m/s, p < 0.05), even though systolic blood pressure was higher in CG (120 ± 11 vs. 132 ± 14 mmHg, p = 0.002). PWV correlated only with age and pulmonary vascular resistance (PVR) in CTEPH (r = 0.45, p = 0.03 and r = 0.43, p = 0.03, respectively). Arterial stiffening defined as PWV > 10 m/s was found in 11 (42%) CTEPH patients and in 5 (23%) cases from CG (p = 0.13). CTEPH patients with PWV > 10 m/s were older (74 ± 8 vs. 66 ± 10 years, p < 0.05), had decreased oxygen saturation (SaO2 89 [73–96]% vs. 96 [85–98]%, p < 0.01) and tended to have higher PVR (8.1 [3.1–14.0] vs. 5.2 [3.1–12.7] HRU, p = 0.10). Conclusions: Arterial stiffness, assessed with PWV, is increased in CTEPH. The elevated PWV is associated with older age, lower SaO2 and higher PVR in CTEPH.

Abstract

Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication   of venous thromboembolism (VTE) resulting from non-dissolving thromboembolic in the pulmonary arteries. Previous observations indicate a higher prevalence of atherosclerosis and cardiovascular risk factors in patients with VTE and CTEPH. The purpose of the present study was to evaluate the arterial stiffening assessed by pulse wave velocity (PWV), a marker of arterial stiffness, in CTEPH patients in comparison with a matched control group (CG). Methods: The study group consisted of 26 CTEPH patients (9 male and 17 female, age 69 ± 10 years) and 22 CG (10 male, 12 female, age 67 ± 8 years). In all subjects a physical examination, carotid-femoral PWV and transthoracic echocardiography (TTE) were performed. Right heart catheterization was done in all CTEPH. Results: CTEPH patients had significantly higher PWV than CG (10.3 ± 2.5 m/s vs. 9 ± 1.3 m/s, p < 0.05), even though systolic blood pressure was higher in CG (120 ± 11 vs. 132 ± 14 mmHg, p = 0.002). PWV correlated only with age and pulmonary vascular resistance (PVR) in CTEPH (r = 0.45, p = 0.03 and r = 0.43, p = 0.03, respectively). Arterial stiffening defined as PWV > 10 m/s was found in 11 (42%) CTEPH patients and in 5 (23%) cases from CG (p = 0.13). CTEPH patients with PWV > 10 m/s were older (74 ± 8 vs. 66 ± 10 years, p < 0.05), had decreased oxygen saturation (SaO2 89 [73–96]% vs. 96 [85–98]%, p < 0.01) and tended to have higher PVR (8.1 [3.1–14.0] vs. 5.2 [3.1–12.7] HRU, p = 0.10). Conclusions: Arterial stiffness, assessed with PWV, is increased in CTEPH. The elevated PWV is associated with older age, lower SaO2 and higher PVR in CTEPH.

Get Citation

Keywords

arterial stiffness, pulse wave velocity, atherosclerosis, chronic thromboembolic pulmonary hypertension

About this article
Title

Increased systemic arterial stiffness in patients with chronic thromboembolic pulmonary hypertension

Journal

Cardiology Journal

Issue

Ahead of print

Article type

Original Article

Published online

2018-09-13

DOI

10.5603/CJ.a2018.0109

Pubmed

30234892

Keywords

arterial stiffness
pulse wave velocity
atherosclerosis
chronic thromboembolic pulmonary hypertension

Authors

Monika Sznajder
Olga Dzikowska-Diduch
Katarzyna Kurnicka
Marek Roik
Dominik Wretowski
Piotr Pruszczyk
Maciej Kostrubiec

References (26)
  1. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016; 37(1): 67–119.
  2. Franchini M, Mannucci PM. Association between venous and arterial thrombosis: clinical implications. Eur J Intern Med. 2012; 23(4): 333–337.
  3. Riva N, Donadini MP, Ageno W. Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation. Thromb Haemost. 2015; 113(6): 1176–1183.
  4. Cavalcante JL, Lima JAC, Redheuil A, et al. Aortic stiffness: current understanding and future directions. J Am Coll Cardiol. 2011; 57(14): 1511–1522.
  5. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006; 27(21): 2588–2605.
  6. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Pressure. 2014; 23(1): 3–16.
  7. McEniery CM, Hall IR, Qasem A, et al. ACCT Investigators. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol. 2005; 46(9): 1753–1760.
  8. Simon AC, Levenson J, Bouthier J, et al. Evidence of early degenerative changes in large arteries in human essential hypertension. Hypertension. 1985; 7(5): 675–680.
  9. Roik M, Wretowski D, Kostrubiec M, et al. High prevalence of severe coronary artery disease in elderly patients with non-operable chronic thromboembolic pulmonary hypertension referred for balloon pulmonary angioplasty. Postepy Kardiol Interwencyjnej. 2016; 12(4): 355–359.
  10. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015; 28(1): 1–39.e14.
  11. Kasprzak JD, Płońska E, Szyszka A, et al. Echokardiografia w praktyce klinicznej–Standardy Sekcji Echokardiografii Polskiego Towarzystwa Kardiologicznego 2007. Kardiol Pol. 2007; 65(9): 1142–62.
  12. Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014; 35(43): 3033–69, 3069a.
  13. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010; 55(13): 1318–1327.
  14. Becattini C, Vedovati MC, Ageno W, et al. Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis. J Thromb Haemost. 2010; 8(5): 891–897.
  15. Safar M. Tętnice w nadciśnieniu tętniczym. Lippincott-Raven, Philadelphia, 1997.
  16. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005; 25(5): 932–943.
  17. Fedullo PF, Auger WR, Kerr KM, et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001; 345(20): 1465–1472.
  18. Galiè N, Kim NHS. Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006; 3(7): 571–576.
  19. O'Connell C, Montani D, Savale L, et al. Chronic thromboembolic pulmonary hypertension. Presse Med. 2015; 44(12 Pt 2): e409–e416.
  20. Jujo T, Sakao S, Ishibashi-Ueda H, et al. Evaluation of the Microcirculation in Chronic Thromboembolic Pulmonary Hypertension Patients: The Impact of Pulmonary Arterial Remodeling on Postoperative and Follow-Up Pulmonary Arterial Pressure and Vascular Resistance. PLoS One. 2015; 10(8): e0133167.
  21. Lang I. Chronic thromboembolic pulmonary hypertension: a distinct disease entity. Eur Respir Rev. 2015; 24(136): 246–252.
  22. Quarck R, Wynants M, Verbeken E, et al. Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension. Eur Respir J. 2015; 46(2): 431–443.
  23. Hunter KS, Lammers SR, Shandas R. Pulmonary vascular stiffness: measurement, modeling, and implications in normal and hypertensive pulmonary circulations. Compr Physiol. 2011; 1(3): 1413–1435.
  24. Chemla D, Castelain V, Hervé P, et al. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J. 2002; 20(5): 1314–1331.
  25. Hou Y, Yuan LJ, Xing CY, et al. Carotid Arterial Stiffness in Patients with Congenital Heart Disease-Related Pulmonary Hypertension Assessed with Radio Frequency Data Technique. Echocardiography. 2015; 32(11): 1676–1680.
  26. Wang LY, Zhu YN, Cui JJ, et al. Subclinical atherosclerosis risk markers in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Respir Med. 2017; 123: 18–27.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl